5 Firms Guide $1.25B BioNTech, CureVac Oncology Deal
By Al Barbarino · June 12, 2025, 8:22 PM BST
German biotech firm BioNTech SE said Thursday that it will acquire CureVac NV, a clinical-stage mRNA specialist, in an all-stock oncology-focused deal valuing it at about $1.25 billion and involving five...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login